Their specificity toward HepG2, a liver cancer cell line, was found by using a competitive inhibition assay in the presence of free Gal and assessing nanoparticle uptake in the presence of free Gal and/or non-galactosylated nanoparticles. This evidence concerns the gene GAL and liver cancer.